Global Personalized Medicine and Companion Diagnostic Market Q2 2013 - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment Research Report
Albany, NY (PRWEB) July 24, 2013 -- This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 261 tables & figures over 205 pages. The personalized medicine (global) market is presented as follows:
By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, decode /Amgen, CELERA, MYRIAD)
By Geography (US, UK, EU)
By Segment (Targeted Therapeutics, Companion Diagnostics, Esoteric tests, Esoteric lab services)
By Sub-market (Companion diagnostics & therapeutic, nutrition & wellness, medical technology, Pharmacogenomics, consumer genomics)
To check out the Complete table of contents, visit: http://www.marketresearchreports.biz/analysis-details/personalized-medicine-and-companion-diagnostic-market-q2-2013-a-strategic-analysis-of-industry-trends-technologies-participants-and-environment
A wealth of financial data & business strategy information is provided including:
Up-to-date company Financials, sales & revenue figures
Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies
Business Model Strategies for Providers. Provider Systems and Academic Medical Centers
Business Model Strategies for Payers & Governments
Private and Public Funding and Personalized Medicine Reimbursement
Revisions to Current Payment Systems and intellectual property
How to Gain Market Penetration in the EU
Cost-effectiveness and Business Value of Personalized Medicine
Consumer genomics and POC market
Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)
Comprehensive account of company product portfolios & kits
Browse All The Report Of This Publisher, Visit: http://www.marketresearchreports.biz/publisher/96
SWOT, Economic & Regulatory Environment specifics include:
Key strengths, weaknesses and threats influencing leading player position within the market
Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
Top fastest growing market segments and emerging opportunities
Top pharmaceutical companies within the IPM by market share and revenue
Comprehensive product portfolios, R&D activity and pipeline therapeutics
M&A activity and future strategies of top personalized medicine pharmacies
Personalized Medicine Regulation (UK, Germany, France, Spain, Italy)
CE-marked Personalized Medicine/Diagnostic Tests
FDA Advances in Personalized Medicine Regulation
For more reports of this category, Visit - http://www.marketresearchreports.biz/category/38
This report highlights a number of significant Indian pharmacy and gives details of their operations, products, financial and business strategy.
23andMe
Affymetrix
Astex Pharmaceuticals
Atossa Genetics
CuraGen
Celera Corporation (Quest Diagnostics)
Celldex Therapeutics
Decode Genetics (Amgen)
Illumine
Genelex
Myriad
Nodality
Qiagen
For Premium Market Research Reports, Visit - http://mresearchreports.blogspot.com/
What you will gain:
An in-depth understanding of the global personalized medicine market and its environment
Current market facts, figures and product lines of key players in the industry
Emerging trends in key markets such as the US, UK, Germany and France
Knowledge of how the personalized medicine market will integrate into the global healthcare market
Technical insights into a new generation sequencing technologies and ultra-high throughput sequencing
Updates on Bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies
FDA approved pharmacogenetic tests and recognized biomarkers
Information on key government and regulatory policies
Strategies on how to adapt and restructure current business models in this industry
This report tackles key concerns to the personalized medicine market such as:
Lack of regulatory policy and legislation in the US and Europe
Reimbursement schemes and payers concerns
Transition of investigational diagnostic assays and therapeutics to clinical practice
Direct to consumer (DTC) test kits and implications for the public
To Buy The Copy of This Report, Visit: http://www.marketresearchreports.biz/analysis/171740
Who should read this report?
Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
Industry professionals and business strategists will discover key information to propel their policies
Investors will gain inside information to dominant players in the industry and future forecasts
Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment
This report will tell you if the companies mentioned are:
Strong, competitive players
Pooling their resources for specific growth and therapeutic areas
Investing strategically in R&D
Have a history of strategic M&A activity
Contact US
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales(at)marketresearchreports(dot)biz
Website: http://www.marketresearchreports.biz/
Blog: http://mrrbiz.blogspot.com/
Blog: http://marketsbuzz.wordpress.com/
Michell Thoras, Market Research Reports, http://www.marketresearchreports.biz/, 1-518-618-1030, [email protected]
Share this article